On June 12th, Merck & Co. said the company is focusing on opportunities in the second and third-generation heart metabolism drug markets, including weight loss treatments. Merck CEO Robert Davis said at the Goldman Sachs Global Healthcare Conference that we are more focused on small molecule oral drugs rather than injectables, which is our preferred route. Merck is looking for market opportunities to increase the additional potential efficacy of weight loss treatments through drug combinations that have 'good tolerability and combinatorial potential.' Davis' comments echo comments made in January of this year when he said that demonstrating efficacy in diseases other than cardiovascular disease, diabetes, and weight management would make drugs easier to obtain insurance reimbursement. It is estimated that by the early 2030s, global annual sales of weight loss drugs will reach about $150 billion, dominated by novo-nordisk's Wegovy and Eli Lilly's Zepbound, both of which are GLP-1 drugs.
默克寻求新一代心脏代谢药物的商机
Merck seeks business opportunities for a new generation of heart metabolic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.